3646 results for «529»

Filter By

3646 results

Mitral interventions: procedural risk assessment and interventions

21 May 2026 – From EuroPCR 2026

Focused on mitral valve interventions, this session covers procedural risk assessment and outcomes following transcatheter edge-to-edge repair (TEER). Topics include predictive risk scores, technical complexity, pulmonary artery pressure indices, right ventricle-pulmonary artery coupling, and novel imaging predictors influencing procedural success and patient prognosis.

Ambiguous left main lesions: how to assess severity and make the right decision

21 May 2026 – From EuroPCR 2026

Addressing the complexities of ambiguous left main coronary lesions, this session elucidates the integration of physiology, intracoronary imaging, and CT scanning for comprehensive assessment. It highlights multimodality diagnostic strategies and decision-making frameworks to guide appropriate revascularization.

Ambiguous left main lesions: how to assess severity and make the right decision

Inflammation and cardiovascular risk

21 May 2026 – From EuroPCR 2026

Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.

Modern risk prediction in TAVI

21 May 2026 – From EuroPCR 2026

This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

STRIVE: intracoronary low-dose recombinant tissue plasminogen activator in primary PCI for STEMI and large thrombus burden

25 Oct 2025

Elad Asher provides his take on the STRIVE study presented by Shamir R. Mehta at TCT 2025, in San Francisco.

Elad Asher

Author

Elad Asher
STRIVE: intracoronary low-dose recombinant tissue plasminogen activator in primary PCI for STEMI and large thrombus burden

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Daniele Giacoppo

Author

Daniele Giacoppo
INFINITY-SWEDEHEART
Didn’t find what you were looking for?